ArticleHaematologica2014

Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy.

Gabriel Etienne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.